journal article·2014-07Open access

Amphiphilic degradable polymers for immobilization and sustained delivery of sphingosine 1-phosphate

Jing Zhang, Jie Song

Acta Biomaterialia· Volume 10· Issue 7

Abstract

Controlled delivery of the angiogenic factor sphingosine 1-phosphate (S1P) represents a promising strategy for promoting vascularization during tissue repair and regeneration. In this study, we developed an amphiphilic biodegradable polymer platform for the stable encapsulation and sustained release of S1P. Mimicking the interaction between amphiphilic S1P and its binding proteins, a series of polymers with hydrophilic poly(ethylene glycol) core and lipophilic flanking segments of polylactide and/or poly(alkylated lactide) with different alkyl chain lengths were synthesized. These polymers were electrospun into fibrous meshes, and loaded with S1P in generally high loading efficiencies (>90%). Sustained S1P release from these scaffolds could be tuned by adjusting the alkyl chain length, blockiness and lipophilic block length, achieving 35-55% and 45-80% accumulative releases in the first 8h and by 7 days, respectively. Furthermore, using endothelial cell tube formation assay and chicken chorioallantoic membrane assay, we showed that the different S1P loading doses and release kinetics translated into distinct pro-angiogenic outcomes. These results suggest that these amphiphilic polymers are effective delivery vehicles for S1P and may be explored as tissue engineering scaffolds where the delivery of lipophilic or amphiphilic bioactive factors is desired.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Sphingolipid Metabolism and Signaling · Endoplasmic Reticulum Stress and Disease · Cellular transport and secretion

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. Angiogenesis and bone repair10.1016/S1359-6446(03)02866-6 ↗
2. Angiogenesis in tissue engineering: breathing life into constructed tissue substitutes10.1089/ten.2006.12.2093 ↗
3. Strategies to direct angiogenesis within scaffolds for bone tissue engineering10.2174/1381612811319190011 ↗
4. Vascularization is the key challenge in tissue engineering10.1016/j.addr.2011.03.004 ↗
5. Vascularized bone tissue engineering: approaches for potential improvement10.1089/ten.teb.2012.0012 ↗
6. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy10.1038/nm1190 ↗
7. Effect of diabetes mellitus on formation of coronary collateral vessels10.1161/01.CIR.99.17.2239 ↗
8. Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications10.1016/S0008-6363(00)00228-5 ↗
9. Osteogenesis and angiogenesis: the potential for engineering bone10.22203/eCM.v015a08 ↗
10. Molecular mechanisms and clinical applications of angiogenesis10.1038/nature10144 ↗
11. Basic and therapeutic aspects of angiogenesis10.1016/j.cell.2011.08.039 ↗
12. Molecular regulation of vessel maturation10.1038/nm0603-685 ↗
13. Endothelialization approaches for viable engineered tissues10.1007/s10456-012-9307-8 ↗
14. In vitro models for the evaluation of angiogenic potential in bone engineering10.1038/aps.2010.143 ↗
15. Advances in growth factor delivery for therapeutic angiogenesis10.1159/000345108 ↗
16. Biomaterial delivery of morphogens to mimic the natural healing cascade in bone10.1016/j.addr.2012.05.006 ↗
17. Controlled growth factor delivery for tissue engineering10.1002/adma.200900241 ↗
18. A role for VEGF as a negative regulator of pericyte function and vessel maturation10.1038/nature07424 ↗
19. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis10.1096/fj.00-0134com ↗
20. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells10.1182/blood.V96.10.3431 ↗
21. Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-310.1042/0264-6021:3480071 ↗
22. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate10.1016/S0092-8674(00)81661-X ↗
23. S1P1 inhibits sprouting angiogenesis during vascular development10.1242/dev.078550 ↗
24. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR210.1016/j.devcel.2012.08.005 ↗
25. Roles of sphingosine-1-phosphate signaling in angiogenesis10.4331/wjbc.v1.i10.298 ↗
26. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization10.1101/gad.1227804 ↗
27. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation10.1172/JCI10905 ↗
28. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation10.1182/blood-2003-02-0460 ↗
29. Sphingosine 1-phosphate accelerates wound healing in diabetic mice10.1016/j.jdermsci.2007.06.002 ↗
30. Sustained delivery of sphingosine-1-phosphate using poly(lactic-co-glycolic acid)-based microparticles stimulates Akt/ERK-eNOS mediated angiogenesis and vascular maturation restoring blood flow in ischemic limbs of mice10.1016/j.ejphar.2010.02.038 ↗
31. Petrie Aronin CE, Wieghaus KA, Botchwey EA. Sustained release of sphingosine 1-phosphate for therapeutic arteriogenesis and bone tissue engineering10.1016/j.biomaterials.2008.03.017 ↗
32. FTY720 promotes local microvascular network formation and regeneration of cranial bone defects10.1089/ten.tea.2009.0539 ↗
33. Delivery of S1P receptor-targeted drugs via biodegradable polymer scaffolds enhances bone regeneration in a critical size cranial defect10.1002/jbm.a.34779 ↗
34. The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY72010.1016/j.biomaterials.2010.04.061 ↗
35. Local delivery of FTY720 accelerates cranial allograft incorporation and bone formation10.1007/s00441-011-1217-3 ↗
36. Delivery of sphingosine 1-phosphate from poly(ethylene glycol) hydrogels10.1021/bm050948r ↗
37. Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis10.1016/j.biomaterials.2010.07.010 ↗
38. The alliance of sphingosine-1-phosphate and its receptors in immunity10.1038/nri2400 ↗
39. Sphingosine 1-phosphate-related metabolism in the blood vessel10.1093/jb/mvi100 ↗
40. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions10.1042/0264-6021:3520809 ↗
41. Evidence that lipoproteins are carriers of bioactive factors10.1161/01.ATV.19.10.2412 ↗
42. The apolipoprotein m-sphingosine-1-phosphate axis: biological relevance in lipoprotein metabolism, lipid disorders and atherosclerosis10.3390/ijms14034419 ↗
43. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M10.1073/pnas.1103187108 ↗
44. Crystal structure of a lipid G protein-coupled receptor10.1126/science.1215904 ↗
45. The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen10.1073/pnas.0906153106 ↗
46. An amphiphilic degradable polymer/hydroxyapatite composite with enhanced handling characteristics promotes osteogenic gene expression in bone marrow stromal cells10.1016/j.actbio.2013.06.013 ↗
47. Ercole F, Graichen FHM, Kyi S, O’Shea MS, Warden AC. Polyurethanes. WO 2009/127012 A1, patent; 2009.
48. Occurrence of 2-hydroxy fatty acids in animal tissues10.1016/S0022-2275(20)40339-6 ↗
49. Breakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase: a revised pathway for the alpha-oxidation of straight chain fatty acids10.1074/jbc.M413362200 ↗
50. Poly(hexyl-substituted lactides): novel injectable hydrophobic drug delivery systems10.1002/jbm.a.30888 ↗
51. Synthesis and ring-opening polymerization of new monoalkyl-substituted lactides10.1002/pola.20251 ↗
52. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells10.1006/bbrc.1999.1586 ↗
53. Attenuation of cell motility observed with high doses of sphingosine 1-phosphate or phosphorylated FTY720 involves RGS2 through its interactions with the receptor S1P10.1111/j.1365-2443.2008.01202.x ↗